hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06292858, orgStudyIdInfo id: IMB071703-101, briefTitle: Safety/Tolerability, PK and Efficacy of IMB071703 Injection in Patients With Advanced Solid Tumors, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-02-24, primaryCompletionDateStruct date: 2025-04, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Beijng Immunoah Pharma Tech Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Subjects with Recurrent or Metastatic，Advanced Solid Tumors, conditionsModule conditions: Recurrent or Metastatic, Advanced Solid Tumors, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SEQUENTIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 93, type: ESTIMATED, armsInterventionsModule interventions name: IMB071703 injection, outcomesModule primaryOutcomes measure: Incidence of adverse events/serious adverse event related with IMB071703 injection, primaryOutcomes measure: Dose-limiting toxicity (DLT), primaryOutcomes measure: Maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of IMB071703 injection, secondaryOutcomes measure: Maximum measured plasma concentration (Cmax) of IMB071703 injection., secondaryOutcomes measure: Time to maximum plasma concentration (Tmax) of IMB071703 injection., secondaryOutcomes measure: Half-life (T1/2) of IMB071703 injection., secondaryOutcomes measure: Immunogenicity profile of IMB071703 injection., secondaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Duration of Response (DOR), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Progression free survival (PFS), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Department of Oncology, Shanghai East Hospital, Tongji University, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200120, country: China, contacts name: Ye Guo, Doctor, role: CONTACT, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06292845, orgStudyIdInfo id: 11272, briefTitle: Ex Vivo Tumor Visualization and Resection Margin Assessment Using Topically Applied Fluorescent Imaging Agents, acronym: SprayDye, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2027-12-01, completionDateStruct date: 2027-12-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Erasmus Medical Center, class: OTHER, descriptionModule briefSummary: This is a proof-of-principle study, that uses freshly resected human solid tumor specimens to assess the performance of topically applied fluorescent imaging agents for the detection of tumor tissue and close / tumor-positive resection margins ex vivo. Surgery will be performed in conformity with hospital protocol. The study will not interfere with the standard clinical care., conditionsModule conditions: Solid Tumor, Adult, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Topical application of a fluorescent imaging agent, outcomesModule primaryOutcomes measure: Tumor-to-background ratio (TBR) of the fluorescence signal on the resection specimen surface and on 3-5 mm thick tissue slices., secondaryOutcomes measure: Imaging agent fluorescence signal intensity on close / tumor-positive resection planes compared with (wide) tumor-negative resection planes, as confirmed by histopathology, secondaryOutcomes measure: Difference in tumor-to-background ratio (TBR) between different imaging time windows, secondaryOutcomes measure: The concordance between the presence of tumor cells and fluorescence signal, secondaryOutcomes measure: Depth of the fluorescence signal on 4-μm tissue slides, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Erasmus University Medical Center, city: Rotterdam, state: Zuid-Holland, zip: 3015 GD, country: Netherlands, geoPoint lat: 51.9225, lon: 4.47917, hasResults: False
protocolSection identificationModule nctId: NCT06292832, orgStudyIdInfo id: MSR/AZAST/AIP029/22/222/8/2023, briefTitle: Erector Spinae Plane Versus Transversus Abdominis Plane Block for Pain Control, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-10, primaryCompletionDateStruct date: 2024-09-10, completionDateStruct date: 2024-09-10, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Al-Azhar University, class: OTHER, descriptionModule briefSummary: The present stratified randomized study aimed to compare the analgesic efficacy and safety profile of ESPB and TAPB used for postoperative pain management in obese and morbidly obese women undergoing CS., conditionsModule conditions: Cesarean Section Complications, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 68, type: ESTIMATED, armsInterventionsModule interventions name: Ultrasound-guided pain block, interventions name: Ultrasound Machine, outcomesModule primaryOutcomes measure: postoperative time to rescue analgesia requirement, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Al-Azhar University, city: Assiut, country: Egypt, contacts name: Warda Ali, role: CONTACT, phone: 010300020456, email: warda2001@hotmail.com, geoPoint lat: 27.18096, lon: 31.18368, hasResults: False
protocolSection identificationModule nctId: NCT06292819, orgStudyIdInfo id: CMUH112-REC2-214, briefTitle: Effects of Photobiomodulation on Insomnia in the Elderly: Clinical Trials of Phototherapy Devices, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-05-31, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: China Medical University Hospital, class: OTHER, descriptionModule briefSummary: The study will recruit 60 participants aged 60 and above, who suffered from insomnia for at least 3 months. Sleep parameters and chronotypes assessed with questionnaires and actigraphy, daytime sleepiness, and biological rhythm (dim light melatonin onset) will be measured. The intervention involves light exposure using a prototype device developed by GCSOL Tech Co., Ltd., a company with expertise in light therapy research and development. Three conditions will be tested (1) bright light; (2) near-infrared light; (3) bright light+ near-infrared light. Data analysis will employ paired t-tests to compare sleep parameters and dim light melatonin onset before and after treatment. Kruskal-Wallis tests and multivariate linear regression will be used to examine differences between intervention groups, controlling for gender and age. Safety analysis will include monitoring adverse events., conditionsModule conditions: Photobiomodulation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Bright light, interventions name: Near-infrared light, interventions name: Bright light+ near-infrared light, outcomesModule primaryOutcomes measure: Actigraphy-derived sleep indicators, primaryOutcomes measure: Dim-light melatonin onset, primaryOutcomes measure: Sleep quality, primaryOutcomes measure: Emotional state, secondaryOutcomes measure: Daytime sleepiness, eligibilityModule sex: ALL, minimumAge: 60 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06292806, orgStudyIdInfo id: 001-2024, briefTitle: Inhibin B/AFC Ratio for Ovarian Response, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2024-03-20, completionDateStruct date: 2025-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Insemine Humen Reproduction Centre, class: NETWORK, descriptionModule briefSummary: Ovarian response to gonadotropin stimulation plays a major role in the success of in vitro fertilization (IVF). Anti-müllerian hormone (AMH), inhibin B, and antral follicle count (AFC) are ovarian reserve markers and also predictors of the ovarian response, as they correlate with the number of oocytes retrieved. Ovarian responsiveness can also be assessed through the Follicular Output Rate (FORT), which evaluates the proportion of follicles that developed during stimulation by the ratio of PFC (preovulatory follicle count) to AFC. FORT highlights that some follicles do not respond to the FSH; therefore, this project proposes an endocrinological approach to this issue by relating AFC to inhibin B and AMH ㅡ hormones produced by granulosa cells, but at different stages of folliculogenesis and with endocrine and paracrine functions, respectively. The inhibin B/AFC and AMH/AFC ratios correlated with FORT and the number of oocytes retrieved may help elucidate the mechanisms involved in follicular responsiveness.A prospective cohort study will be conducted with patients of the Insemine Center for Human Reproduction. Antral follicle count and AMH measurement will be performed before IVF cycle initiation, and inhibin B measurement will be carried out on a blood sample collected on the fifth day of ovarian stimulation. The primary outcomes will be the Follicular Output Rate (FORT) and the number of oocytes retrieved. Secondary outcomes include the number of metaphase II oocytes, oocyte quality, fertilization rate and embryo quality., conditionsModule conditions: IVF, conditions: Infertility, Female, conditions: Ovulation Disorder, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 144, type: ESTIMATED, armsInterventionsModule interventions name: FSH-R, outcomesModule primaryOutcomes measure: serum Inhibin B levels, primaryOutcomes measure: serum Anti Mullerian Hormone levels, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06292793, orgStudyIdInfo id: STUDY00004696, briefTitle: Cyclical Sighing for Pain, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-12-13, primaryCompletionDateStruct date: 2024-02-26, completionDateStruct date: 2024-02-26, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Florida State University, class: OTHER, descriptionModule briefSummary: This is a single-site, two-arm, parallel-group randomized clinical trial (RCT). The clinical effects of a 4-minute audio-recorded cyclical sighing intervention for orthopedic patients will be investigated relative to a 4-minute audio-recoding about pain psychoeducation., conditionsModule conditions: Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 81, type: ACTUAL, armsInterventionsModule interventions name: Pain Coping Information, interventions name: Cyclical Sighing, outcomesModule primaryOutcomes measure: Change in Pain Unpleasantness Numeric Rating Scale, secondaryOutcomes measure: Change in Pain Intensity Numeric Rating Scale, secondaryOutcomes measure: Change in Anxiety Numeric Rating Scale, secondaryOutcomes measure: Change in Depression Numeric Rating Scale, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tallahassee Orthopedic Clinic (TOC), city: Tallahassee, state: Florida, zip: 32308, country: United States, geoPoint lat: 30.43826, lon: -84.28073, hasResults: False
protocolSection identificationModule nctId: NCT06292767, orgStudyIdInfo id: 2023/462, briefTitle: Cardiopulmonary Bypass on Mechanical Power and Postoperative Pulmonary Complications, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2025-01-15, completionDateStruct date: 2025-04-25, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: TC Erciyes University, class: OTHER, descriptionModule briefSummary: During cardiopulmonary bypass (CPB), oxygenation of the patient on the pump can be left completely under pump control, or the lungs can be ventilated with low tidal volume to reduce atelectasis. In recent years, the concept of mechanical power has been used to determine the extent of ventilator-related lung damage. This concept of mechanical power, by which the energy transferred by the ventilator to the lungs can be calculated, will be measured at certain intervals in CPB surgery patients on the pump and compared between the two groups. The investigators aimed to investigate the effect of two different ventilation methods on mechanical power and its relationship with postoperative pulmonary complications., conditionsModule conditions: Postoperative Pulmonary Atelectasis, conditions: Pneumothorax, conditions: Pneumonia, conditions: Ards, conditions: Respiratory Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 250, type: ESTIMATED, armsInterventionsModule interventions name: mechanical power calculation, outcomesModule primaryOutcomes measure: mechanical power, secondaryOutcomes measure: mechanical power, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06292741, orgStudyIdInfo id: 4956, briefTitle: Autonomic Involvement in Patient With Cognitive Decline, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-01-11, primaryCompletionDateStruct date: 2024-07, completionDateStruct date: 2026-01, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS, class: OTHER, descriptionModule briefSummary: Prospective interventional study with a device for comparing autonomic parameters among patients with different forms of cognitive decline, conditionsModule conditions: Dementia, Mild, conditions: Dementia of Alzheimer Type, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Sudoscan, outcomesModule primaryOutcomes measure: evaluation of the prevalence in autonomic dysfunction in patients with MCI and dementia, secondaryOutcomes measure: correlation between the extent of autonomic involvement and the severity of cognitive decline, secondaryOutcomes measure: evaluation of the type of cognitive disorder, defined by the scores obtained in the MMSE between subjects with and without autonomic dysfunction., eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Clinica della memria- Fondazione Policlinico Agostino Gemelli IRCCS, status: RECRUITING, city: Roma, state: Lazio, zip: 00168, country: Italy, contacts name: Camillo Marra, MD, role: CONTACT, phone: 0630154333, email: camillo.marra@policlinicogemelli.it, geoPoint lat: 41.89193, lon: 12.51133, hasResults: False
protocolSection identificationModule nctId: NCT06292728, orgStudyIdInfo id: ENDOPLY1, briefTitle: ENDOPLY System in Humans: a Pilot Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2025-05, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: ENDOPLY, class: OTHER, collaborators name: Just 4 Device s.r.o., descriptionModule briefSummary: Prospective, non-randomized study aimed at defining the initial pattern of gastric plication with the ENDOPLY System, and assess feasibility, ergonomics and safety of the device Prospective, single-centre, open label, consecutive enrolment, conditionsModule conditions: Obesity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DEVICE_FEASIBILITY, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: ENDOPLY System, outcomesModule primaryOutcomes measure: Time of duration of the ENDOPLY System study procedure, primaryOutcomes measure: Number of ligatures placed by ENDOPLY System study procedure, primaryOutcomes measure: Gastric perforation events, primaryOutcomes measure: Gastrointestinal bleeding events, primaryOutcomes measure: Initial weight-loss, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Institut klinické a experimentální medicíny (IKEM), Klinika hepatogastroenterologie, city: Prague, zip: 14021, country: Czechia, contacts name: Evžen Machytka, MD, Ph.D., role: CONTACT, email: evmac@seznam.cz, contacts name: Evžen Machytka, MD, Ph.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 50.08804, lon: 14.42076, hasResults: False
protocolSection identificationModule nctId: NCT06292715, orgStudyIdInfo id: Microwave Ablation01, briefTitle: Microwave Ablation With Splenic Artery Occlusion for Secondary Hypersplenism, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-20, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-12-31, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Tianjin Medical University Cancer Institute and Hospital, class: OTHER, descriptionModule briefSummary: This study assesses the effectiveness of microwave ablation of the spleen in conjunction with splenic artery occlusion for treating secondary hypersplenism., conditionsModule conditions: Secondary Hypersplenism, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 35, type: ESTIMATED, armsInterventionsModule interventions name: microwave ablation of the spleen, interventions name: Splenic artery balloon implantation, outcomesModule primaryOutcomes measure: Portal venous pressure, primaryOutcomes measure: Hepatic artery blood flow velocity, primaryOutcomes measure: Routine blood test, primaryOutcomes measure: Adverse Events, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tianjin Medical University Cancer Institute & Hospital, status: RECRUITING, city: Tianjin, state: Tianjin, zip: 300060, country: China, contacts name: Huikai Li, role: CONTACT, phone: +862223340123, phoneExt: 3091, email: lihuikai@tjmuch.com, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06292689, orgStudyIdInfo id: IRB-2024-5(IIT), briefTitle: A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-22, primaryCompletionDateStruct date: 2026-03-22, completionDateStruct date: 2027-03-22, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: Zhejiang Cancer Hospital, class: OTHER, collaborators name: Akeso, collaborators name: Innovent Biologics, Inc., descriptionModule briefSummary: To evaluate the efficacy and safety of cardunolizumab in combination with/without chemotherapy ± bevacizumab for recurrent or metastatic vulvar and vaginal cancers that are not amenable to radical treatment., conditionsModule conditions: Vulvar and Vaginal Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Cardunolizumab, outcomesModule primaryOutcomes measure: Objective Response Rate (ORR), secondaryOutcomes measure: Progression-free survival (PFS), secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Disease control rate (DCR), secondaryOutcomes measure: Duration of response (DOR), secondaryOutcomes measure: Adverse events (AEs), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zhejiang Cancer Hospital, city: Hangzhou, state: Zhejiang, zip: 310005, country: China, contacts name: Hanmei Lou, MD., role: CONTACT, phone: +8619817462599, email: louhm@zjcc.org.cn, contacts name: Hanmei Lou, MD., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 30.29365, lon: 120.16142, hasResults: False
protocolSection identificationModule nctId: NCT06292676, orgStudyIdInfo id: ObGynEASC004, briefTitle: Emergency Home Delivery. Learning Skills for Medical Doctors and Nurses. Kirkpatrick Levels of Learning, acronym: ERdeliv, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2024-05-20, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-05, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: G. d'Annunzio University, class: OTHER, descriptionModule briefSummary: Mannequin training for emergency home delivery on medical doctors and nurses, conditionsModule conditions: Home Birth Delivery, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: skills retained for home birth delivery in emergency, outcomesModule primaryOutcomes measure: Kirkpatrick levels improvement, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Claudio Celentano, status: RECRUITING, city: Pescara, state: Italia, zip: 65100, country: Italy, contacts name: Claudio Celentano, MD, role: CONTACT, phone: 3285577305, email: celentanoclaudio70@gmail.com, geoPoint lat: 42.4584, lon: 14.20283, hasResults: False